, unlabeled substances were added to the injected solution to demonstrate self-inhibition and cross-inhibition for several of the acids and lack of cross-inhibition between pyruvate and glucose, phenylalanine, or arginine. The self-inhibiting effects of the addition to the injected solution of unlabeled acid on the uptake of the same 14C-labeled acid were studied using acetate, propionate, pyruvate, L-lactate, and butyrate as test substances. The maximum concentration of unlabeled acid added was 10 mM except for L-lactate where it was carried out to 15 mM.
The cross-inhibiting effects of the addition to the injected Fig. 1 . No significant cross-inhibition of octanoate or decanoate is observed (Fig. 1) .
Cross-inhibition of L-phenylalanine, L-arginine, or Dglucose uptake by pyruvate appears to be negligible (Table  3) .
DISCUSSION
Methodology. The methodology used here is well suited to the study of metabolizable solutes. The penetration of BBB presumably occurs before a significant biotransformation of the labeled compound can occur, since the brain uptake takes place during the first l-2 set after injection.
--wea--------------------a----------
Since the blood in the artery visibly clears during the injection, the bolus of injected solution probably remains with approximately its original chemical composition when it passes through the brain microcirculation. This allows the creation in the injected solution of known concentrations of unlabeled solutes and the measurement of any effects of these unlabeled species on the brain uptake of the radiolabeled species. In this manner, relative affinities of the unlabeled and labeled species for carrier transport sites can be measured.
Self-inhibition and cross-inhibition can thus be In addition to the influence of lipid solubility on uptake, the data presented here suggest that the rate of BBB penetration of the shorter, more hydrophilic acids is greater than that expected on the basis of lipid solubility.
That this represents carrier-mediated transport is supported by the partial saturability of the brain uptakes of these shorter chain smaller acids. If the uptake were lipid mediated, it should be independent of injected concentration. Further support is given to the presence of a specific carrier transport mechanism by the stereospecificity of the uptake of L-lactate. If the uptake of L-lactate were due only to its lipid solubility, it should not be stereospecific, since the lipid solubilities of the L and D enantiomorphs presumably are identical. The lactate stereospecificity here parallels the stereospecificity of brain uptake found after intravenous injection of labeled L-and D-lactate (5).
If the uptakes of only the three-carbon monocarboxylic acids are considered, pyruvate uptake exceeds that of propionate, despite the additional weak hydrogen bonding resulting from the substitution of the oxygen on the center carbon. The hydroxyl group on the center carbon of lactate would be expected to make lactate much more hydrophilic than propionate, yet it still exhibits an appreciable uptake. The very low uptake of n-lactate may represent uptake due to its slight lipid solubility, whereas the difference between D and L uptake presumably represents the much greater affinity of the L-enantiomorph for the monocarboxylic carrier system. (1, 12) . The penetration of red cells by organic acids has been extensively studied (Z-4, 1 l), but specific attempts to demonstrate carrier-mediated transport were unsuccessful (1 1 ), although the short-chain monocarboxylic acids used in the present study were not examined.
The teleology of this fourth BBB transport system, which appears to result only in an increased BBB permeability to short-chain monocarboxylic acids, remains obscure. It may function to allow an increased flux of short-chain acids into brain where they may serve as metabolic substrates in normal or pathologic states. Although the present studies only demonstrate facilitated passage of organic acids from blood to brain, the carrier could also function to allow the efflux from brain of lactate in brain in normal and hypoxic states (8). 
